On 5 August 2011, orphan designation (EU/3/11/890) was granted by the European Commission to Kowa Pharmaceutical Europe Co. Ltd, United Kingdom, for peretinoin for the treatment of hepatocellular carcinoma.
The sponsorship was transferred to Kowa Pharmaceutical Europe GmbH, Germany, in July 2018.
|Disease / condition||
Treatment of hepatocellular carcinoma
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.